Traders should monitor Lifecore’s progress on these site transfers and any future announcements regarding commercial ramp-up timelines. The 2028 revenue contribution suggests a medium-term catalyst; consider positioning ahead of potential scale-up updates or additional contract wins.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 26 $3.87entry
- T+1 · 8mo ago −5.43%α −3.75% · $3.66
- T+5 · 8mo ago −0.78%α −2.41% · $3.84
- T+20 · 7mo ago +29.72%α +19.05% · $5.02
- T+60 · 5mo ago +45.27%α +31.32% · $5.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lifecore Biomedical announced two new CDMO manufacturing agreements with an existing U.S. biopharmaceutical customer: one for a commercial site transfer of a currently marketed product, and another to expand manufacturing of an ophthalmic product into a new delivery system previously made in Europe. These agreements are expected to contribute to commercial revenue starting in 2028 and mark the company's fourth site transfer win in five months, reinforcing its strategic focus on late-stage, high-value programs.
Key Facts
- Lifecore signed two manufacturing agreements with an existing U.S. biopharmaceutical customer.
- One agreement involves a commercial site transfer of a currently marketed product, requiring technical transfer and PPQ batches at commercial scale.
- The second agreement expands manufacturing of an ophthalmic product to a new delivery system, shifting production from Europe to Lifecore.
- These are the fourth commercial site transfer agreements signed in five months.
- Management expects both programs to contribute to commercial revenue in 2028.
- The deals are additive to Lifecore’s late-stage pipeline and reflect growing customer trust.
Financial Impact
Expected to generate meaningful commercial revenue starting in 2028, though no specific dollar amounts disclosed.
Risk Factors
- Revenue contribution is not expected until 2028, introducing execution and timing risk.
- Forward-looking statements are subject to regulatory, technical, and customer-related uncertainties.
- No financial terms or deal values were disclosed, limiting near-term financial impact assessment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262848 |
Track record
20 reports on LFCR
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.34% at T+20 after the Jul 2, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
- Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
- Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
- Nov 4, 202612d ago 8-K Bearish 6/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
- Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
- Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
- Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers